Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists

PURPOSE: The prevalence of off-label anticancer drug use is not well characterized. The extent of off-label use is a policy concern because the clinical benefits of such use to patients may not outweigh costs or adverse health outcomes. METHODS: Prescribing data from IntrinsiQ Intellidose data syste...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Conti, Rena M., Bernstein, Arielle C., Villaflor, Victoria M., Schilsky, Richard L., Rosenthal, Meredith B., Bach, Peter B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3595423/
https://ncbi.nlm.nih.gov/pubmed/23423747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.7252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados